Scl-70 Antibody
Here’s what it reflects — and what to do about it.
Longetic pulls together every lab and record you’ve had, follows how Scl-70 Antibody changes over time, and explains what’s shifting — so you walk into your next appointment prepared, with reminders for retests along the way.
What is Scl-70 Antibody?
Detects antibodies against topoisomerase I, closely associated with diffuse systemic sclerosis and organ involvement.
Anti-Scl-70 antibodies, also called anti-topoisomerase I antibodies, target an enzyme involved in DNA structure and are one of the more disease-specific autoantibodies for systemic sclerosis (scleroderma). This marker relates to the immune system and connective tissues, including skin, blood vessels, and internal organs such as the lungs. Clinicians typically order Scl-70 testing, often as part of an ENA panel, in people with symptoms suggestive of scleroderma, such as skin thickening, Raynaud phenomenon, or unexplained shortness of breath, particularly when a positive ANA result has already been found. Because Scl-70 positivity has been associated in research with more extensive skin and lung involvement, it may help clinicians anticipate which body systems deserve closer monitoring. As with other autoantibodies, results are interpreted alongside clinical findings, imaging, and other laboratory tests rather than as a stand-alone diagnostic tool.
Lifestyle factors that influence this marker
- Follow a balanced, anti-inflammatory diet with an emphasis on vegetables, fruit, and healthy fats
- Protect hands and feet from cold exposure to help support circulation
- Engage in regular gentle movement and stretching to help maintain skin and joint flexibility
- Prioritize consistent, restorative sleep
- Manage stress through relaxation techniques
- Avoid smoking, which may affect circulation and lung-related symptoms in connective tissue conditions
Tests often checked alongside this
- ANA (Antinuclear Antibody) — the broader screening test Scl-70 is typically reflexed from
- RNP Antibody — relevant when overlap with mixed connective tissue disease is considered
- Pulmonary function tests — often monitored together given lung involvement in scleroderma
- Complete blood count — helps assess overall health status
How this can show up in how you look and feel
- May be associated with skin thickening or tightness in some individuals
- May be associated with color changes in fingers or toes with cold exposure (Raynaud phenomenon)
- May be associated with shortness of breath or reduced exercise tolerance
- May be associated with digestive symptoms such as reflux in some cases
What can affect this marker
- Age
- Sex
- Inflammation
- Lab variability between testing methods
What to track over time
- Whether Scl-70 levels track alongside skin, lung, or vascular symptoms over time
- How this result fits with pulmonary function and imaging monitoring if ordered
- Repeat testing may be considered if new symptoms suggest disease progression
What to ask your doctor
- What does a positive Scl-70 result mean for monitoring my skin and lungs?
- Should I have pulmonary function testing given this result?
- How does this fit with my ANA and other ENA panel results?
- How often should this and related organ-system monitoring be repeated?
This glossary entry is for informational purposes only and is not a substitute for professional medical advice. Read our Terms of Use.
References
About our sources
Official sources
Government health agencies, national institutes, and intergovernmental bodies whose guidelines carry regulatory or policy weight.
Clinical / professional
Medical societies, specialty colleges, and professional associations whose consensus statements reflect clinical practice standards.
Peer-reviewed research
Original research articles and systematic reviews published in indexed journals and verified through PubMed or DOI.
